Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/antithrombotic-drug-therapy-in-cardiovascular-disease/askari/descriptif_3187224
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3187224

Antithrombotic Drug Therapy in Cardiovascular Disease, 2010 Contemporary Cardiology Series

Langue : Anglais

Coordonnateurs : Askari Arman T., Lincoff A. Michael

Couverture de l’ouvrage Antithrombotic Drug Therapy in Cardiovascular Disease

Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies.

Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticoagulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, Antithrombotic Drug Therapy in Cardiovascular Disease presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT).

Part 1: Basic Principles Chapter 1 The Platelet in Arterial and Venous Thrombosis Peter Kelly, MD Edward F. Plow, PhD Chapter 2 The Coagulation Cascade in Arterial and Venous Thrombosis Kandice Marchant, MD, PhD Chapter 3 The Link Between Thrombosis and Inflammation John H. Cleator, MD Mark Robbins, MD Chapter 4 Genetics of Thrombosis Svati H. Shah, MD, MHS Richard C. Becker, MD Part II: Antithrombotic Therapy for Stable Coronary Atherosclerotic Disease Chapter 5 Aspirin for Primary and Secondary Prevention Jinesh Kochar, MD, MPH J, Michael Gaziano, MD, MPH Chapter 6 Thienopyridines in Stable CAD Patients Dipak Kotecha, MBChB., MRCP. Marcus D. Flather, MBBS, FRCP Part III: Antithrombotic Therapy for NSTE ACS Chapter 7 Anti-platelet Therapies: Aspirin, Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors Saif Anwaruddin MD Deepak L. Bhatt MD Chapter 8 Unfractionated Heparin and Enoxaparin Pierluigi Tricoci, MD, MHS, PhD Kenneth W. Mahaffey, MD Chapter 9 The Direct Thrombin Ihibitors Tyler Taigen, MD James Harvey, MD A. Michael Lincoff, MD Chapter 10 Synthetic Factor Xa Inhibition, Fondaparinux Michael S. Kim, MD Robert L. Page, Pharm.D Ivan P. Casserly, MBBCh Part IV: Antithrombotic Therapy for STEMI Chapter 11 Antiplatelet Therapies: Aspirin,Clopidogrel and thienopyridines and Glycoprotien IIb/IIIa Inhibitors Rory B. Weiner, MD Marc S. Sabatine, MD, MPH Chapter 12 Antithrombin Therapies: Unfractionated Heparin, Enoxaparin, Direct Thrombin Inhibitors, Fondaparinux John M. Galla, MD Arman T. Askari, MD Chapter 13 Fibrinolysis and Facilitated PCI RyanD. Christofferson, MD Sorin J. Brener, MD Part V: Antithrombotic Therapy in Interventional Cardiology Chapter 14 Antithrombotic Therapy in Percutaneous Coronary Intervention Adrian W. Messerli, MD Chapter 15 Antithrombotic Therapy in Carotid and Peripheral Intervention Thomas J. Helton, MD Samir R. Kapadia, MD Chapter 16 Monitoring of Antithrombotic Therapies Kristofer Dosh, MD Steven Steinhubl, MD Part VI: Antithrombotic Therapy in Venous Thromboembolic Disease Chapter 17 Antithrombotic Therapy for DVT/PE Esther S.H. Kim, MD John R. Bartholomew, MD Chapter 18 Fibrinolysis for PE Stavros V. Konstantinides, MD Chapter 19 Duration of Anticoagulation Following VTE Clive Kearon, MB MRCPI FRCPC PhD Part VII: Clinical Considerations Chapter 20 Antithrombotic Therapy for Atrial Fibrillation Carmel M. Halley MD Allan L. Klein MD Chapter 21 Antithrombotic Therapy for Valvular Heart Disease Noah Rosenthal MD Brian D. Hoit MD Chapter 22 Antithrombotic Therapy for Cardiomyopathy Zuheir Abrahams MD PhD George Sokos MD W. H. Wilson Tang MD Chapter 23 Heparin-Induced Thrombocytopenia John R. Bartholomew, MD Chapter 24 'Resistance' to Antiplatelet Therapies Gerald C. Koenig, MD, PhD Hitinder S. Gurm, MD

Comprehensive overview of the pathophysiology, including the genetics, of arterial and venous thrombosis

Detailed, up-to-date data regarding the use of the currently available antithrombotic therapies for commonly-encountered clinical situations in Cardiology

Provides rapid access to instructional discussions of various therapies

Includes supplementary material: sn.pub/extras

Ouvrage de 475 p.

19.3x26 cm

Sous réserve de disponibilité chez l'éditeur.

Prix indicatif 232,09 €

Ajouter au panier

Ouvrage de 475 p.

19.3x26 cm

Sous réserve de disponibilité chez l'éditeur.

Prix indicatif 210,99 €

Ajouter au panier